AI Supercomputer For Design And Drug Discovery

This synergy enables AI-driven breakthroughs, making simulations faster, more scalable, and more energy-efficient across multiple disciplines, from semiconductor design to drug development.

Cadence Design Systems, Inc. has officially unveiled its new Millennium M2000 Supercomputer at CadenceLIVE Silicon Valley 2025, a significant step in revolutionizing AI-accelerated simulation for industries spanning from semiconductor design to drug discovery. Featuring NVIDIA Blackwell systems, this cutting-edge supercomputer delivers up to 80 times the performance and 20 times lower power consumption compared to traditional CPU-based systems, providing unmatched efficiency and speed for a wide range of workloads.

It integrates Cadence’s simulation software with NVIDIA’s Blackwell-accelerated hardware, including the HGX B200 systems and RTX PRO 6000 Blackwell Server Edition GPUs, optimized for Electronic Design Automation (EDA), system design analysis (SDA), and life sciences applications. This synergy enables AI-driven breakthroughs, making simulations faster, more scalable, and more energy-efficient across multiple disciplines, from semiconductor design to drug development.

– Advertisement –

“The Millennium M2000 will propel the next phase of AI-accelerated engineering by enhancing designer productivity, helping tackle complex problems in semiconductor and drug discovery design,” said Anirudh Devgan, President and CEO of Cadence. “This powerful platform leverages massive scalability and AI to push the boundaries of innovation.”

This supercomputer promises transformative advancements across various industries. In semiconductor design, it allows faster simulations for 3D-IC and advanced packaging, reducing simulation times from weeks to mere hours. In autonomous system design, it enables more efficient data center operations, digital twins, and virtual wind tunnels for drones, robotics, and autonomous transportation systems. For the life sciences sector, Cadence’s Orion® Molecular Design Platform on the M2000 accelerates drug discovery, enabling researchers to explore more design scenarios in less time.

The supercomputer is available both in the cloud and as an on-premises solution. It is already being used by leading organizations, including Ascendance, Boom Supersonic, MediaTek, Supermicro, and Treeline Biosciences.